Adipotide, popularly known as FTPP, is an experimental weight loss treatment that causes programmed cell death of cells by eliminating their blood supply. This innovative compound has been studied in many animal research studies; therefore, it could be a game-changing approach to managing obesity and metabolic disorders.
How Adipotide Works
The mechanism of action of Adipotide involves targeting the blood vessels that supply white adipose tissue. It binds receptors on the vascular structure of WAT, disrupting the vascular supply, leading to the starvation and eventual death of fat cells. This reduces fat mass and may improve metabolic health by decreasing insulin resistance and inflammation.
Research on Adipotide
Adipotide and Fat Loss
Adipotide was developed and entered phase one clinical trials in 2011, investigating its ability to induce fat cell apoptosis. Preclinical studies in rhesus monkeys have demonstrated that Adipotide specifically acts on the blood vessels feeding the white adipose tissue, causing death to fat cells. This leads to rapid weight loss, reduced body mass index, and increased sensitivity to insulin. The treated monkeys also showed decreased food intake, suggesting that it may affect appetite.
Adipotide and Cancer
Although highly speculative, preliminary studies conducted on animals indicated that the mechanism through which Adipotide destroys blood vessels may help with cancer therapy. Prohibitin is the molecule this peptide largely targets in fat cells. It has also been linked with certain types of cancer.
Cancer cells need a large amount of blood to grow and metastasize. Focusing on prohibiting cancer cells could provide a way to treat cancer without damaging the surrounding healthy tissue.
Adipotide and Glucose tolerance
Glucose tolerance means having higher-than-normal levels of blood sugar. Patients generally diagnose this condition with blood tests or by administering a glucose tolerance test, in which a patient consumes a certain amount of sugar, and then blood sugar levels are measured.
You can treat high glucose levels with diet and exercise, but these methods demand motivation and dedication. They also need a considerable amount of time to show the first results. Research involving Adipotide has revealed that this peptide produces weight-independent and rapid improvement in glucose tolerance. This means that Adipotide is able to reduce glucose tolerance regardless of the impact of weight.
In other words, losing fat content is important, not weight. These findings not only help us understand how this peptide works but also open new opportunities for developing innovative treatments for pre-diabetes and diabetes conditions and mechanisms that lead to the development of this illness. There are some doubts about whether this peptide directly causes fat loss or only minimizes food intake, which directly affects fat loss.
According to research done on animals, scientists concluded that Adipotide potentially causes fat loss. This hypothesis is supported by the fact that Adipotide can change cell density without affecting glucose tolerance and causing weight loss.
Conclusion
The main field of research involving this peptide relates to diabetes and weight loss. As mentioned earlier, it targets specific cells and blood vessels and shows minimal side effects. However, more research is required before this peptide could be used on humans.
References:
- Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011 Nov 9;3(108):108ra112. doi: 10.1126/scitranslmed.3002621. PMID: 22072637; PMCID: PMC3666164.
- Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18637-42. doi: 10.1073/pnas.1114503108. Epub 2011 Nov 2. PMID: 22049339; PMCID: PMC3219136.
- Daquinag AC, Tseng C, Salameh A, Zhang Y, Amaya-Manzanares F, Dadbin A, Florez F, Xu Y, Tong Q, Kolonin MG. Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development. Cell Death Differ. 2015 Feb;22(2):351-63. doi: 10.1038/cdd.2014.148. Epub 2014 Oct 24. PMID: 25342467; PMCID: PMC4291494.
- Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes. 2012 Sep;61(9):2299-310. doi: 10.2337/db11-1579. Epub 2012 Jun 25. PMID: 22733798; PMCID: PMC3425411.
Our support team is at your service, ensuring customer satisfaction.
